{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T04:26:32Z","timestamp":1781670392752,"version":"3.54.5"},"reference-count":122,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the National Cancer Center"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jncc.2025.11.001","type":"journal-article","created":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T12:30:16Z","timestamp":1766838616000},"page":"88-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3256-5992","authenticated-orcid":false,"given":"Viriya","family":"Keo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4731-0762","authenticated-orcid":false,"given":"Xiaodong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3163-380X","authenticated-orcid":false,"given":"Jonathan C.","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jindan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jncc.2025.11.001_bib0001","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jncc.2025.11.001_bib0002","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0003","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2017.77.6880","article-title":"Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study","volume":"36","author":"Aggarwal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0004","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jncc.2025.11.001_bib0005","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1158\/2159-8290.CD-11-0130","article-title":"Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets","volume":"1","author":"Beltran","year":"2011","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0006","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.CCR-24-2061","article-title":"Framework for the pathology workup of metastatic castration-resistant prostate cancer biopsies","volume":"31","author":"Haffner","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0007","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1038\/modpathol.2017.164","article-title":"Neuroendocrine tumors of the prostate","volume":"31","author":"Fine","year":"2018","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0008","first-page":"756","article-title":"Proposed morphologic classification of prostate cancer with neuroendocrine differentiation","volume":"38","author":"Epstein","year":"2014","journal-title":"AJSP"},{"key":"10.1016\/j.jncc.2025.11.001_bib0009","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ejca.2019.08.011","article-title":"Clinical features of neuroendocrine prostate cancer","volume":"121","author":"Conteduca","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jncc.2025.11.001_bib0010","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/1078-0432.CCR-13-1982","article-title":"Rb loss is characteristic of prostatic small cell neuroendocrine carcinoma","volume":"20","author":"Tan","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0011","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1126\/science.aah4199","article-title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance","volume":"355","author":"Ku","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jncc.2025.11.001_bib0012","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1158\/1078-0432.CCR-15-1259","article-title":"Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers","volume":"22","author":"Aparicio","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0013","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1126\/science.aah4307","article-title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","volume":"355","author":"Mu","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.jncc.2025.11.001_bib0014","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1158\/2159-8290.CD-16-1174","article-title":"Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer","volume":"7","author":"Zou","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0015","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1097\/MOP.0b013e32801080fe","article-title":"Childhood tumors of the nervous system as disorders of normal development","volume":"18","author":"Grimmer","year":"2006","journal-title":"Curr Opin Pediatr"},{"key":"10.1016\/j.jncc.2025.11.001_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.121550","article-title":"Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer","volume":"15","author":"Mosquera","year":"2013","journal-title":"Neoplasia"},{"key":"10.1016\/j.jncc.2025.11.001_bib0017","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ccell.2016.03.001","article-title":"N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cells","volume":"29","author":"Lee","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0018","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.ccell.2016.09.005","article-title":"N-Myc induces an EZH2-mediated transcriptional program driving neuroendocrine prostate cancer","volume":"30","author":"Dardenne","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0019","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.ccr.2008.12.005","article-title":"Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma","volume":"15","author":"Otto","year":"2009","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0020","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-18-1912","article-title":"A phase II trial of the aurora kinase A inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: efficacy and biomarkers","volume":"25","author":"Beltran","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0021","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166248","article-title":"Chemokine receptor CXCR7 activates aurora kinase A and promotes neuroendocrine prostate cancer growth","volume":"133","author":"Gritsina","year":"2023","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0022","doi-asserted-by":"crossref","first-page":"3924","DOI":"10.1172\/JCI127961","article-title":"N-Myc\u2013mediated epigenetic reprogramming drives lineage plasticity in advanced prostate cancer","volume":"129","author":"Berger","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0023","doi-asserted-by":"crossref","first-page":"3372","DOI":"10.1038\/s41467-021-23780-y","article-title":"Temporal evolution of cellular heterogeneity during the progression to advanced AR-negative prostate cancer","volume":"12","author":"Brady","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0024","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1038\/onc.2017.50","article-title":"FOXA1 inhibits prostate cancer neuroendocrine differentiation","volume":"36","author":"Kim","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.jncc.2025.11.001_bib0025","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41586-019-1318-9","article-title":"FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes","volume":"571","author":"Adams","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0026","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41422-019-0204-1","article-title":"Altered chromatin recruitment by FOXA1 mutations promotes androgen independence and prostate cancer progression","author":"Xu","year":"2019","journal-title":"Cell Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0027","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.ccell.2022.10.011","article-title":"FOXA2 drives lineage plasticity and kit pathway activation in neuroendocrine prostate cancer","volume":"40","author":"Han","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0028","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1038\/s41467-021-22139-7","article-title":"Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer","volume":"12","author":"Baca","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0029","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1038\/s41588-022-01045-8","article-title":"HOXB13 suppresses de novo lipogenesis through HDAC3-mediated epigenetic reprogramming in prostate cancer","volume":"54","author":"Lu","year":"2022","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0030","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1038\/s41598-021-82472-1","article-title":"Neuroendocrine prostate cancer has distinctive, non-prostatic HOX code that is represented by the loss of HOXB13 expression","volume":"11","author":"Cheng","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.jncc.2025.11.001_bib0031","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/path.6216","article-title":"Characterization of HOXB13 expression patterns in localized and metastatic castration-resistant prostate cancer","volume":"262","author":"Patel","year":"2024","journal-title":"J Pathol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0032","doi-asserted-by":"crossref","first-page":"4492","DOI":"10.1172\/JCI128212","article-title":"Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer","volume":"129","author":"Labrecque","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0033","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1038\/s41588-025-02265-4","article-title":"NKX2-1 drives neuroendocrine transdifferentiation of prostate cancer via epigenetic and 3D chromatin remodeling","volume":"57","author":"Lu","year":"2025","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0034","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8290.CD-15-1263","article-title":"The master neural transcription factor BRN2 is an androgen receptor\u2013suppressed driver of neuroendocrine differentiation in prostate cancer","volume":"7","author":"Bishop","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0035","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41467-018-08133-6","article-title":"ONECUT2 is a driver of neuroendocrine prostate cancer","volume":"10","author":"Guo","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0036","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1038\/s41591-018-0241-1","article-title":"ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis","volume":"24","author":"Rotinen","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jncc.2025.11.001_bib0037","doi-asserted-by":"crossref","first-page":"7740","DOI":"10.1093\/nar\/gkae547","article-title":"ONECUT2 acts as a lineage plasticity driver in adenocarcinoma as well as neuroendocrine variants of prostate cancer","volume":"52","author":"Qian","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0038","doi-asserted-by":"crossref","first-page":"eadf6732","DOI":"10.1126\/scitranslmed.adf6732","article-title":"Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer","volume":"15","author":"Yamada","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jncc.2025.11.001_bib0039","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","article-title":"ZNF397 deficiency triggers TET2-driven lineage plasticity and AR-targeted therapy resistance in prostate cancer","volume":"14","author":"Xu","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0040","article-title":"Androgen deprivation-induced TET2 activation fuels prostate cancer progression via epigenetic priming and slow-cycling cancer cells","author":"Li","year":"2025","journal-title":"bioRxiv [Preprint]"},{"key":"10.1016\/j.jncc.2025.11.001_bib0041","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13148-015-0074-4","article-title":"Polycomb-mediated silencing in neuroendocrine prostate cancer","volume":"7","author":"Clermont","year":"2015","journal-title":"Clin Epigenetics"},{"key":"10.1016\/j.jncc.2025.11.001_bib0042","article-title":"Mevrometostat (PF-06821497), an enhancer of zeste homolog 2 (EZH2) inhibitor, in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC): a randomized dose-expansion study","volume":"43","author":"Schweizer","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0043","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.neo.2020.04.002","article-title":"Alternative splicing of LSD1+8a in neuroendocrine prostate cancer is mediated by SRRM4","volume":"22","author":"Coleman","year":"2020","journal-title":"Neoplasia (New York)"},{"key":"10.1016\/j.jncc.2025.11.001_bib0044","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.167440","article-title":"LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function","volume":"8","author":"Kumaraswamy","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jncc.2025.11.001_bib0045","doi-asserted-by":"crossref","first-page":"4923","DOI":"10.1158\/1078-0432.CCR-20-4968","article-title":"Bet bromodomain inhibition blocks an AR-repressed, E2F1-activated treatment-emergent neuroendocrine prostate cancer lineage plasticity program","volume":"27","author":"Kim","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0046","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/j.apsb.2025.01.007","article-title":"Effective therapeutic targeting of tumor lineage plasticity in neuroendocrine prostate cancer by BRD4 inhibitors","volume":"15","author":"Zhang","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.jncc.2025.11.001_bib0047","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/path.6280","article-title":"Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer","volume":"263","author":"Choo","year":"2024","journal-title":"J Pathol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0048","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1158\/2767-9764.CRC-23-0250","article-title":"Concurrent targeting of HDAC and PI3K to overcome phenotypic heterogeneity of castration-resistant and neuroendocrine prostate cancers","volume":"3","author":"Zhang","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0049","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1038\/s41467-021-26042-z","article-title":"Subtype heterogeneity and epigenetic convergence in neuroendocrine prostate cancer","volume":"12","author":"Cejas","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0050","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1038\/s41467-022-29963-5","article-title":"ASCL1 activates neuronal stem cell-like lineage programming through remodeling of the chromatin landscape in prostate cancer","volume":"13","author":"Nouruzi","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0051","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1038\/s41467-020-19328-1","article-title":"Role of specialized composition of SWI\/SNF complexes in prostate cancer lineage plasticity","volume":"11","author":"Cyrta","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0052","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1158\/1541-7786.MCR-18-1101","article-title":"Whole-genome and transcriptional analysis of treatment-emergent small-cell neuroendocrine prostate cancer demonstrates intraclass heterogeneity","volume":"17","author":"Aggarwal","year":"2019","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0053","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.146827","article-title":"Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer","volume":"6","author":"Brennen","year":"2021","journal-title":"JCI Insight"},{"issue":"6","key":"10.1016\/j.jncc.2025.11.001_bib123","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.cell.2008.01.018","article-title":"Foxa1 translates epigenetic signatures into enhancer-driven lineage-specific transcription","volume":"132","author":"Lupien","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0054","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","article-title":"Prostate cancer reactivates developmental epigenomic programs during metastatic progression","volume":"52","author":"Pomerantz","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms4972","article-title":"Cooperativity and equilibrium with FOXA1 define the androgen receptor transcriptional program","volume":"5","author":"Jin","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0056","doi-asserted-by":"crossref","first-page":"8153","DOI":"10.1093\/nar\/gkw498","article-title":"FOXA1 potentiates lineage-specific enhancer activation through modulating TET1 expression and function","volume":"44","author":"Yang","year":"2016","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0057","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.1158\/0008-5472.CAN-12-3468","article-title":"Androgen receptor-independent function of FOXA1 in prostate cancer metastasis","volume":"73","author":"Jin","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0058","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1172\/JCI122367","article-title":"Targeting FOXA1-mediated repression of TGF-\u03b2 signaling suppresses castration-resistant prostate cancer progression","volume":"129","author":"Song","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0059","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1242\/dev.00432","article-title":"Hoxb13 is required for normal differentiation and secretory function of the ventral prostate","volume":"130","author":"Economides","year":"2003","journal-title":"Development"},{"key":"10.1016\/j.jncc.2025.11.001_bib0060","doi-asserted-by":"crossref","first-page":"4131","DOI":"10.1158\/1078-0432.CCR-21-3603","article-title":"Acetylated Hoxb13 regulated super enhancer genes define therapeutic vulnerabilities of castration-resistant prostate cancer","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0061","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.4161\/cc.9.22.13973","article-title":"REST and CoREST are transcriptional and epigenetic regulators of seminal neural fate decisions","volume":"9","author":"Qureshi","year":"2010","journal-title":"Cell Cycle"},{"key":"10.1016\/j.jncc.2025.11.001_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41420-024-02031-1","article-title":"Androgen deprivation induces neuroendocrine phenotypes in prostate cancer cells through CREB1\/EZH2-mediated downregulation of rest","volume":"10","author":"Zheng","year":"2024","journal-title":"Cell Death Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0063","doi-asserted-by":"crossref","first-page":"4698","DOI":"10.1158\/1078-0432.CCR-15-0157","article-title":"SRRM4 expression and the loss of rest activity may promote the emergence of the neuroendocrine phenotype in castration-resistant prostate cancer","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0064","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/modpathol.2017.44","article-title":"FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate","volume":"30","author":"Park","year":"2017","journal-title":"Mod Pathol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ccr.2010.05.024","article-title":"Siah2-dependent concerted activity of HIF and FoXa2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors","volume":"18","author":"Qi","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0066","doi-asserted-by":"crossref","first-page":"4914","DOI":"10.1038\/s41467-024-49234-9","article-title":"FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer","volume":"15","author":"Wang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.185952","article-title":"ASCL1 regulates and cooperates with FOXA2 to drive terminal neuroendocrine phenotype in prostate cancer","volume":"9","author":"Nouruzi","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jncc.2025.11.001_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0053701","article-title":"Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer","volume":"8","author":"Kregel","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jncc.2025.11.001_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107669","article-title":"Combined TP53 and RB1 loss promotes prostate cancer resistance to a spectrum of therapeutics and confers vulnerability to replication stress","volume":"31","author":"Nyquist","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.jncc.2025.11.001_bib0070","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1172\/JCI135373","article-title":"LIN28B promotes the development of neuroendocrine prostate cancer","volume":"130","author":"Lovnicki","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0071","doi-asserted-by":"crossref","first-page":"6532","DOI":"10.1158\/1078-0432.CCR-19-0498","article-title":"BRN4 is a novel driver of neuroendocrine differentiation in castration-resistant prostate cancer and is selectively released in extracellular vesicles with BRN2","volume":"25","author":"Bhagirath","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0072","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.celrep.2018.09.082","article-title":"Pan-cancer landscape of aberrant DNA methylation across human tumors","volume":"25","author":"Saghafinia","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jncc.2025.11.001_bib0073","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41588-020-0648-8","article-title":"The DNA methylation landscape of advanced prostate cancer","volume":"52","author":"Zhao","year":"2020","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0074","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.162907","article-title":"Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer","volume":"8","author":"Sayar","year":"2023","journal-title":"JCI Insight"},{"key":"10.1016\/j.jncc.2025.11.001_bib0075","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1172\/JCI131041","article-title":"Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer","volume":"130","author":"Beltran","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jncc.2025.11.001_bib0076","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-21-3762","article-title":"Detecting neuroendocrine prostate cancer through tissue-informed cell-free DNA methylation analysis","volume":"28","author":"Berchuck","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0077","first-page":"OF1","article-title":"Noninvasive detection of neuroendocrine prostate cancer through targeted cell-free DNA methylation","author":"Franceschini","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0078","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1038\/s41591-023-02605-z","article-title":"Liquid biopsy epigenomic profiling for cancer subtyping","volume":"29","author":"Baca","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.jncc.2025.11.001_bib0079","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.1158\/0008-5472.CAN-22-1123","article-title":"The 5-hydroxymethylcytosine landscape of prostate cancer","volume":"82","author":"Sj\u00f6str\u00f6m","year":"2022","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0080","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.devcel.2021.02.005","article-title":"FoxA-dependent demethylation of DNA initiates epigenetic memory of cellular identity","volume":"56","author":"Reizel","year":"2021","journal-title":"Dev Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0081","doi-asserted-by":"crossref","first-page":"10657","DOI":"10.1158\/0008-5472.CAN-07-2498","article-title":"A polycomb repression signature in metastatic prostate cancer predicts cancer outcome","volume":"67","author":"Yu","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0082","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1101\/gr.131508.111","article-title":"Cooperation between polycomb and androgen receptor during oncogenic transformation","volume":"22","author":"Zhao","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0083","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cell.2006.02.041","article-title":"A bivalent chromatin structure marks key developmental genes in embryonic stem cells","volume":"125","author":"Bernstein","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0084","doi-asserted-by":"crossref","first-page":"2808","DOI":"10.1016\/j.celrep.2018.11.035","article-title":"Polycomb- and methylation-independent roles of EZH2 as a transcription activator","volume":"25","author":"Kim","year":"2018","journal-title":"Cell Rep"},{"key":"10.1016\/j.jncc.2025.11.001_bib0085","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","article-title":"An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer","volume":"23","author":"Davies","year":"2021","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0086","doi-asserted-by":"crossref","first-page":"6779","DOI":"10.1038\/s41467-024-51156-5","article-title":"Lineage-specific canonical and non-canonical activity of EZH2 in advanced prostate cancer subtypes","volume":"15","author":"Venkadakrishnan","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0087","doi-asserted-by":"crossref","first-page":"653","DOI":"10.2217\/epi-2023-0374","article-title":"Combined therapy targeting AR and EZH2 curbs castration-resistant prostate cancer enhancing anti-tumor T-cell response","volume":"16","author":"Fischetti","year":"2024","journal-title":"Epigenomics"},{"key":"10.1016\/j.jncc.2025.11.001_bib0088","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.eururo.2016.04.028","article-title":"SRRM4 drives neuroendocrine transdifferentiation of prostate adenocarcinoma under androgen receptor pathway inhibition","volume":"71","author":"Li","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0089","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1158\/1078-0432.CCR-15-1449","article-title":"Targeting MYCN-driven transcription by BET-bromodomain inhibition","volume":"22","author":"Henssen","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0090","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-20-0751","article-title":"Targeting the p300\/CBP axis in lethal prostate cancer","volume":"11","author":"Welti","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0091","doi-asserted-by":"crossref","unstructured":"Luo J, Chen Z, Qiao Y, et al. P300\/CBP degradation is required to disable the active AR enhanceosome in prostate cancer. bioRxiv [Preprint]. 2024:2024.03.29.587346. https:\/\/doi.org\/10.1101\/2024.03.29.587346.","DOI":"10.1101\/2024.03.29.587346"},{"key":"10.1016\/j.jncc.2025.11.001_bib0092","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.18632\/oncotarget.23111","article-title":"SIRT1 contributes to neuroendocrine differentiation of prostate cancer","volume":"9","author":"Ruan","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.jncc.2025.11.001_bib0093","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbamcr.2021.119085","article-title":"AMPK\/SIRT1 signaling through p38MAPK mediates interleukin-6 induced neuroendocrine differentiation of LNCaP prostate cancer cells","volume":"1868","author":"Natani","year":"2021","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0094","doi-asserted-by":"crossref","unstructured":"De Almeida FN, Vasciaveo A, Antao AM, et al. A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer. bioRxiv [Preprint]. 2024:2024.08.24.609538. https:\/\/doi.org\/10.1101\/2024.08.24.609538.","DOI":"10.1101\/2024.08.24.609538"},{"key":"10.1016\/j.jncc.2025.11.001_bib0095","doi-asserted-by":"crossref","first-page":"eabe1505","DOI":"10.1126\/science.abe1505","article-title":"Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets","volume":"376","author":"Tang","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.jncc.2025.11.001_bib0096","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","article-title":"An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression","volume":"84","author":"Shrestha","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0097","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.ccell.2020.03.001","article-title":"Loss of CHD1 promotes heterogeneous mechanisms of resistance to AR-targeted therapy via chromatin dysregulation","volume":"37","author":"Zhang","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0098","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/s41586-021-04246-z","article-title":"Targeting SWI\/SNF ATPases in enhancer-addicted prostate cancer","volume":"601","author":"Xiao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0099","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1016\/j.ccell.2024.06.006","article-title":"Targeting the mSWI\/SNF complex in POU2F-POU2AF transcription factor-driven malignancies","volume":"42","author":"He","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jncc.2025.11.001_bib0100","doi-asserted-by":"crossref","unstructured":"Thienger P, Rubin PD, Yao X, et al. Androgen receptor-negative prostate cancer is vulnerable to SWI\/SNF-targeting degrader molecules. bioRxiv [Preprint]. 2024:2024.03.24.586276. https:\/\/doi.org\/10.1101\/2024.03.24.586276.","DOI":"10.1101\/2024.03.24.586276"},{"key":"10.1016\/j.jncc.2025.11.001_bib0101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1101\/gad.350269.122","article-title":"Pioneer factor ASCL1 cooperates with the mSWI\/SNF complex at distal regulatory elements to regulate human neural differentiation","volume":"37","author":"P\u0103un","year":"2023","journal-title":"Genes Dev"},{"key":"10.1016\/j.jncc.2025.11.001_bib0102","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41586-019-1182-7","article-title":"Transcription factors and 3D genome conformation in cell-fate decisions","volume":"569","author":"Stadhouders","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0103","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1038\/s41467-021-23142-8","article-title":"Impact of DNA methylation on 3D genome structure","volume":"12","author":"Buitrago","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0104","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1093\/nar\/gkae054","article-title":"Tet-mediated DNA methylation dynamics affect chromosome organization","volume":"52","author":"Tian","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0105","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201883119","article-title":"Polycomb-mediated genome architecture enables long-range spreading of H3K27 methylation","volume":"119","author":"Kraft","year":"2022","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jncc.2025.11.001_bib0106","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/s41586-022-05365-x","article-title":"Subtype-specific 3D genome alteration in acute myeloid leukaemia","volume":"611","author":"Xu","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0107","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nature16490","article-title":"Insulator dysfunction and oncogene activation in IDH mutant gliomas","volume":"529","author":"Flavahan","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0108","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/s41588-018-0338-y","article-title":"EZH2 oncogenic mutations drive epigenetic, transcriptional, and structural changes within chromatin domains","volume":"51","author":"Donaldson-Collier","year":"2019","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0109","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1038\/s41588-021-00842-x","article-title":"Histone acetylation dynamics modulates chromatin conformation and allele-specific interactions at oncogenic loci","volume":"53","author":"Sungalee","year":"2021","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0110","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1101\/gr.201517.115","article-title":"Three-dimensional disorganization of the cancer genome occurs coincident with long-range genetic and epigenetic alterations","volume":"26","author":"Taberlay","year":"2016","journal-title":"Genome Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0111","doi-asserted-by":"crossref","first-page":"4154","DOI":"10.1038\/s41467-019-12079-8","article-title":"A high-resolution 3D epigenomic map reveals insights into the creation of the prostate cancer transcriptome","volume":"10","author":"Rhie","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.jncc.2025.11.001_bib0112","article-title":"Chromosome compartmentalization alterations in prostate cancer cell lines model disease progression","volume":"221","author":"San Martin","year":"2021","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0113","doi-asserted-by":"crossref","first-page":"5833","DOI":"10.1158\/0008-5472.CAN-21-2056","article-title":"Reorganization of the 3D genome pinpoints noncoding drivers of primary prostate tumors","volume":"81","author":"Hawley","year":"2021","journal-title":"Cancer Res"},{"key":"10.1016\/j.jncc.2025.11.001_bib0114","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1038\/s41588-024-01826-3","article-title":"Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer","volume":"56","author":"Zhao","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.jncc.2025.11.001_bib0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-020-01476-1","article-title":"Single-cell analysis supports a luminal-neuroendocrine transdifferentiation in human prostate cancer","volume":"3","author":"Dong","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0116","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/s41585-020-00400-w","article-title":"Genomic and phenotypic heterogeneity in prostate cancer","volume":"18","author":"Haffner","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jncc.2025.11.001_bib0117","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/s41586-022-05023-2","article-title":"Spatially resolved clonal copy number alterations in benign and malignant tissue","volume":"608","author":"Erickson","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.jncc.2025.11.001_bib0118","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nm.4053","article-title":"Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer","volume":"22","author":"Kumar","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.jncc.2025.11.001_bib0119","article-title":"Single-cell transcriptional regulation and genetic evolution of neuroendocrine prostate cancer","volume":"25","author":"Wang","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.jncc.2025.11.001_bib0120","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1158\/2159-8290.CD-24-0296","article-title":"The epigenetic hallmarks of cancer","volume":"14","author":"Esteller","year":"2024","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jncc.2025.11.001_bib0121","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1158\/1078-0432.CCR-22-3743","article-title":"Immunogenomic landscape of neuroendocrine prostate cancer","volume":"29","author":"Bhinder","year":"2023","journal-title":"Clin Cancer Res"}],"container-title":["Journal of the National Cancer Center"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500119X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S266700542500119X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T12:31:23Z","timestamp":1771331483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S266700542500119X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":122,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S266700542500119X"],"URL":"https:\/\/doi.org\/10.1016\/j.jncc.2025.11.001","relation":{},"ISSN":["2667-0054"],"issn-type":[{"value":"2667-0054","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Journal of the National Cancer Center","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jncc.2025.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Chinese National Cancer Center. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}